Cipla (CIPLA) — Announcement

1 Announcement 🔴 High Importance ✨ Positive 📄 PDF

Cipla Limited announced the launch of Yurpeak® (tirzepatide), a weekly injectable therapy for obesity and type 2 diabetes, under a distribution agreement with Eli Lilly. Available in six strengths (2.5–15 mg), the drug will be priced identically to Mounjaro®. Cipla plans nationwide distribution leveraging its strong network, with Lilly handling manufacturing. The launch expands Cipla's chronic disease portfolio and positions it to capture India's large diabetes and obesity treatment market.

2 Announcement Neutral 📄 PDF

Cipla Limited received an ESG rating of 66 from NSE Sustainability Ratings & Analytics Limited, a SEBI-registered provider, for FY 2024-25. The rating was communicated on December 9, 2025. This independent assessment reflects the company's environmental, social, and governance performance across the fiscal year, providing investors with a standardized measure of Cipla's sustainability credentials.

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this announcement affect Cipla Limited's outlook?" "What did Cipla Limited announce on 10 December 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 10 December 2025

JIOFIN Jio Financial Services Limited Corporate Action LUPIN Lupin Limited Corporate Action TRENT Trent Limited Insider Trading HINDUNILVR Hindustan Unilever Limited Corporate Action TCS Tata Consultancy Services Limited Board Meeting TATASTEEL Tata Steel Limited Board Meeting

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.